This document provides information about the "Cell Based Assays Americas" conference to be held on July 19-20, 2012 in Boston, USA. The conference will focus on advances in cell-based assays for drug discovery, development and toxicity testing. It will explore new techniques and applications of cell-based assays, including their use in reducing costs and risks in the drug development process. Speakers will discuss topics like high content screening strategies, 3D tissue models, stem cell technologies and interpreting results from cell-based assays. The agenda provides details of presentations on developing cell-based assay platforms and applications in areas like neurodegeneration, cardiotoxicity screening and kinase inhibitor mechanisms of action. The conference aims to highlight future growth opportunities in
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
SMi Group's 6th annual Pre-Filled Syringes conference & exhibition is already Europe's leading event. This year it will be better than ever. Check out the programme.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Keeping the (Adventitious) Virus Out of the (Adeno-Associated) VirusMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/2VRylbi
How can you keep an adventitious virus from contaminating your gene therapy that is delivered by an adeno virus vector? As viral vector bioprocessing advances, regulatory requirements for viral safety will as well. Learn how to define your viral clearance strategy for AAV delivered gene therapies.
How do you define a strategy for viral clearance for a process that inherently aims at purifying a virus?
Gene delivery using AAV has received a boost from two major approvals and the nearly 300 programs in the clinic. Novel gene therapies using viral vectors enable companies to transform the lives of people living with certain rare and ultra-rare diseases where treatments are often not available currently. Amongst a multitude of challenges in viral vector bioprocessing, uncertainty in regulatory expectations is a major challenge to gene therapy developers. Regulatory requirements are evolving as the science and manufacturing matures with more stringent measures for viral safety assurance expected for future approvals.
Learn how to implement techniques for adventitious virus removal in your viral vector process; we will focus on strategies for viral clearance along your journey towards commercial readiness of AAV-based processes.
In this webinar, you will learn:
• AAV process flows and focus areas for viral safety
• Strategies for implementing viral clearance measures in bioprocessing
• Case studies and data driven approaches on log reduction values (LRV) in a viral vector process
• Best practices and evaluation roadmaps on conducting viral clearance studies
Presented by: Ratish Krishnan, Senior Strategy Consultant, Novel Modalities Bioprocessing
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
SMi Group's 6th annual Pre-Filled Syringes conference & exhibition is already Europe's leading event. This year it will be better than ever. Check out the programme.
Cancer Diagnostics Reference Laboratory / NeoGenomics April 2014 investors company overview presentation. This presentation highlights the following:
--Fast growing cancer genetics lab servicing Oncologists, Pathologists and Hostpitals
--Strategic client partnerships created by "Tech-Only" model
--Dynamic, rapidly-growing and consolidating industry
Industry-leading revenue & test volume growth
--Strong productivity and operating leverage leading to accelerating cash flow and net income
--Strong Management Team with large cap lab experience
Keeping the (Adventitious) Virus Out of the (Adeno-Associated) VirusMerck Life Sciences
Watch the presentation of this webinar here: https://bit.ly/2VRylbi
How can you keep an adventitious virus from contaminating your gene therapy that is delivered by an adeno virus vector? As viral vector bioprocessing advances, regulatory requirements for viral safety will as well. Learn how to define your viral clearance strategy for AAV delivered gene therapies.
How do you define a strategy for viral clearance for a process that inherently aims at purifying a virus?
Gene delivery using AAV has received a boost from two major approvals and the nearly 300 programs in the clinic. Novel gene therapies using viral vectors enable companies to transform the lives of people living with certain rare and ultra-rare diseases where treatments are often not available currently. Amongst a multitude of challenges in viral vector bioprocessing, uncertainty in regulatory expectations is a major challenge to gene therapy developers. Regulatory requirements are evolving as the science and manufacturing matures with more stringent measures for viral safety assurance expected for future approvals.
Learn how to implement techniques for adventitious virus removal in your viral vector process; we will focus on strategies for viral clearance along your journey towards commercial readiness of AAV-based processes.
In this webinar, you will learn:
• AAV process flows and focus areas for viral safety
• Strategies for implementing viral clearance measures in bioprocessing
• Case studies and data driven approaches on log reduction values (LRV) in a viral vector process
• Best practices and evaluation roadmaps on conducting viral clearance studies
Presented by: Ratish Krishnan, Senior Strategy Consultant, Novel Modalities Bioprocessing
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
Extracting clinical value from next gen sequencingWinton Gibbons
It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing.
To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations.
As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required.
The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful.
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Viral Risk Mitigation - A Global Regulatory PerspectiveMilliporeSigma
Looking for insights into current global regulatory expectations for viral safety? Read the special report from BioProcess International, in collaboration with Martin Wisher, Senior Regulatory Consultant focusing on BioReliance biosafety® services.
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
The only event in Asia bringing global oligonucleotide and peptide leaders together to discuss current strategies and trends to accelerate promising molecules from research to commercialization.
The Clinical Trial in Oncology event on 1-2 December 2009 in Munich will show you how to utilise target approaches to optimize your clinical research and enhance your patient enrolment, data quality and much more.
Extracting clinical value from next gen sequencingWinton Gibbons
It has become cliché in the clinical environment, and genetic sequencing realm, that there is a glut of sequence data. The conundrum is how to translate or transform the overabundance of data into clinically useful knowledge. This situation has only grown more acute since the introduction of next gen sequencing.
To arrive at the clinical knowledge, there needs to be a concentric series of integrated capabilities, and the necessary capacity. The core is of course the sequencing process itself, the IT tools to process it, and the human expertise. However, the essentials in the first two aspects, sequencing and IT, need to exist, and thereby create opportunities for organizations.
As there are numerable subtleties even within the essential capabilities, a single organization may not be able to develop all under one roof. Nor may certain abilities yet exist sufficiently. However, a complete ecosystem at best, or promising potential at worst, is still required.
The attached presentation illustrates the high-level transformation frameworks for this, and the subsequent translation of data to be clinically useful.
Anthony Presentation DIA Florida Ctd Nov2007AKTaylor
Creating a business process that is accurate, predictable, and capable of
meeting the changing needs for disclosing information about clinical trials
in multiple study registries and results databases is difficult. Companies
need to leverage their current clinical trial process, determine if the disclosure
steps will be centralized or decentralized, determine how much to
leverage technology, and decide whether, and how, to use outside
resources. During this session, we will hear how a large pharma, a small
biopharmaceutical company, and a device company developed their clinical
trial disclosure business process.
Holistic Approaches to Virus Risk MitigationMilliporeSigma
Presented at INTERPHEX on March 21-23, 2017.
Regulatory guidelines have shaped industry best practices around adventitious virus contamination risk mitigation in terms of patient safety. A recent survey indicated that the cost to remediate a virus contamination can run into millions of dollars, not including commercial impact. Today, the industry is taking a closer look at minimizing the business risk associated with viral contaminations and is taking a more holistic view of risk mitigation. This approach includes virus prevention and detection in addition to removal. From cell culture seed train to final fill vial, the discussion will describe the potential risks associated with different areas of biotech processes and what can be done to minimize adventitious virus risk in those areas. The overarching strategy of risk mitigation will include evaluation of raw materials, modified expression systems, environmental controls, upstream and downstream processing, testing and regulatory considerations.
Viral Risk Mitigation - A Global Regulatory PerspectiveMilliporeSigma
Looking for insights into current global regulatory expectations for viral safety? Read the special report from BioProcess International, in collaboration with Martin Wisher, Senior Regulatory Consultant focusing on BioReliance biosafety® services.
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
Welcome to the M Lab™ Collaboration Centers – where customers can use non-GMP lab spaces to operate equipment, evaluate processes and receive real-time technical support without disrupting production.
Plan your visit: www.merckmillipore.com/mlab
The only event in Asia bringing global oligonucleotide and peptide leaders together to discuss current strategies and trends to accelerate promising molecules from research to commercialization.
IHPL presents Maharajas Express, World's Leading Luxury Train in a Special Departure on 23rd of September 2015 across the famed Golden Triangle Tour in India.
Investment contribution to strategic objectives!
Business cases based on RoI or NPV seldom contribute to any benefits over time or support the strategic objectives. Return on Strategy is an excellent method to calculate strategic contribution per invested SEK.
The main hypothesis of a traditional business case is that we can isolate the effects of an investment over time (3-5 years) to calculate its benefit contribution. But the fact is that the hypothesis is far from true. In the ‘new normal’ we need new investment management methods that eliminates ‘the X factor’ (unpredictability).
The Goodwind Company (together with Pro4u and ValueMiner) has developed a concept "Return on Strategy" to evaluate and optimize the strategic contribution of the Investment portfolio. How much objective contribution do we get per invested SEK?
Presentation given by Mark James, VP of Economic and Business Development at AEP, at the Appalachian Power Economic Development Forum held in Beckley, WV, on May 16, 2013.
The conference will provide an interactive networking forum to both further develop and answer your queries through a vibrant exhibition room full of technology providers showcasing their technologies and other solutions, poster presentation sessions, expert led case study presentations, a high-level panel discussion, a round table discussion session, and interactive Q&A sessions from a 40-strong speaker faculty examining topics on 4 separate tracks outlined below.
Pharmaceutical Product & Process Design & QualityAjaz Hussain
A reflection on progress made, and challenges to be addressed, in realizing the desired state articulated by the the FDA Initiative on Pharmaceutical Quality for the 21st Century.
- Discover new methods for managing clinical next-gen data with insights from Pfizer, Boston Children’s Hospital and AstraZeneca
- Uncover and critique the latest technologies out there for you to use in clinical trials. Mayo Clinic, Merck and Harvard Medical School let you into their trade secrets
- Hear the genomics strategies that Roche, Millennium and Regeneron are using for discovery and validation of clinically actionable biomarkers
-Bristol-Myers Squibb, Takeda and Partners Healthcare the role that NGS can play when implementing an effective strategy in the lab to speed up CDx development
- Learn how to integrate molecular details into medical decision making, with fresh data from Washington University School of Medicine and Genzyme
The Pistoia Alliance is examining the challenges of the Faster Safe Companion Diagnostics (CDx) by Aligning Discovery & Clinical Data in the Regulatory Domain.
The slides discuss whether the data standards used in the research environment be aligned better with the data standards used in the regulated environment? If so, the time and cost of the development of NGS-based CDx could be reduced.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
P 058 Advances And Progress In Drug Designkprior88
SMi\'s 12th Annual Drug Design Conference will present attendees with an in-depth view into the developments and challenges within the Drug Design field
An overview of the oncology clinical trials network (CTNeT) which is being implemented throughout Texas.
The non-profit network is a first of its kind and combines the innovative science of Texas cancer centers with the expertise and resources of both academic and community oncologists throughout the state.
To learn more, visit www.ctnet.org
ExL Pharma Clinical Trials Phase I and Phase IIa Conference Brochure: Phase 1...bryonmain
There is a pill or treatment for almost everything, or at least, that is how it seems. However, the amount of effort that goes into a pill or treatment before it is launched is extensive, expensive and often inefficient.
Efficiency and innovation go hand-in-hand with R&D and the development of clinical trials, however, FDA regulations and clinical trial standardization end up stifling these two key factors. This leads to drawn out processes that cost companies hundreds of millions of dollars before the drugs hit the market. Efforts have been made to increase efficiency in phase I/IIA with some companies changing their clinical trial manifestos to suit the available patient population at clinical sites, but more emphasis should be placed on creating more efficient processes for first in human studies by optimizing pharmacokinetics/pharmacodynamics, dosage selection, technological advancements to improve efficacy and structured patient mapping to increase successful trial and patient recruitment opportunities.
This program will give delegates the opportunity to share proven strategies between companies to help increase efficiency in this space and streamline processes to cut down costs. This event will bring together large and small companies and experts in this space to share best practices to decrease the financial drain theses phases have on the overall clinical trial budget. Life science corporations need the most up-to-date tools and practices to increase success by streamlining processes, sharing successful biomarker strategies, anticipating dosing quantities, and optimizing healthy or specialty patient recruitment and retention. Current strategies include patient mapping before organizing and setting up a clinical space, tailoring early phase clinical trials to patient populations, purchasing biological samples from collection companies, and trying to accelerate the process by submitting for breakthrough therapy designation.
Top Reasons To Attend
Identify Compound Development Strategies to Optimize Success in Clinical Trials
Learn Best Practices for Early Decision-Making Through Analysis of Biomarker Utility in Drug Development
Utilize Analytical Technology to Evaluate Multiple Configurations of a Small Molecule to Increase the Feasibility of Drug in Clinical Trials
Implement Adaptive Design in Proof of Concept Studies to Increase Efficiency, Decrease Time and Decrease Overall Cost
Explore the Seamless Development of Phase I to Phase II in Clinical Trials
NINE Case Studies and a Panel Session on Early Phase Clinical Trial Strategies
Innovation in Phase 1 Clinical DevelopmentElisa_Ramella
Practical app roaches to
phase I trial develop ment
to enable faster go / no -go
decision s, reduce co st and
speed time to market
www.phase1clinicaldevelopment.com
1. CALL
NOW FOR
EARLY BIRD
Cell Based
DISCOUNTS
Assays Americas
Market prospects for more cost-effective drug discovery, development
and toxicity testing using advances in methodology
July 19th - 20th, 2012, The Seaport Hotel, Boston, USA BOOK NOW!
Key Speakers
Sashi Nadanaciva, Principal Scientist, Pfizer R&D
Douglas Auld, Sr. Research Investigator I, Novartis
Arijit Chakravarty, Senior Scientist, Millennium Pharmaceuticals
Regis Doyonnas, Senior Principle Scientist, Pfizer
Okechukwu Ukairo, Sr. Principal Scientist, Hepregen Corporation
Robert Graves, Senior Scientist, GE Healthcare
Marcie Glicksman, Director Lab for Drug Discovery, Harvard NeuroDiscovery Center
Deborah Moshinsky, Founder and President, Cell Assay Innovations
Jim Beltzer, Senior Cell Processing Specialist, Terumo BCT Robert Graves, Senior Scientist, GE Healthcare
Tetsuro Wakatsuki, Co-Founder & Chief Scientific Officer, InvivoSciences
Grace Wong, CEO, ActoKine Therapeutics
Mehmet Fatih Yanik, Assoc. Professor, MIT
Shantanu Singh, Research Fellow, Imaging Platform, Broad Institute of Harvard and MIT
Grant Cameron, RAFT Development Director, TAP Biosystems
Thorsten Gorba, Director, CNS Assay Screening and Development, StemCells, Inc.
Peter Sartipy, Senior Principal Scientist, Department Head, Cellectis Stem Cells
Silver Sponsor Exhibitors matrical
bioscience
Driving the Industry Forward | www.futurepharmaus.com
Media Partners Organised By
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/CellBasedAssaysUSA
2. Conference Introduction
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
Dear Colleague,
Drugs recalls due to toxicity not only have a huge effect on the cost of Who should attend this conference?
developing new therapeutics but it also leads to many years of wasted
research. That is why it is vital to get things right from the outset with more Presidents, Chief Executives, Chief Scientific Officers, Chief
precise testing of new leads using more accurate in-vitro models. High
Throughput Screening using biochemical assays has been a mainstay of the Operating Officers, Senior Vice Presidents, Vice Presidents,
pharmaceutical industry in the past, but with the cost of developing a single
Heads, Senior Directors, Directors, Clinicians, Principal
lead reaching exorbitant amounts, it is now necessary to look at more cost-
efficient methods that more accurately represent the in-vivo environment. Scientists, Principal Investigators, Managers, Project/Team
cell based assay platform has now been integrated into the HTS
The Leaders in:
pipeline to provide more accurate analyses of new drug leads and their
activity in-vivo. It already makes up 50% of the HTS activity by the top
• Bioanalytical Development
pharmaceutical companies and the industry is set to grow at a rate of
15% CAGR by 20151. In addition to being a more accurate platform for
• High-Throughput/High-Content Screening Operations
developing drugs, it also reduces costs incurred by toxicology testing in
animals and mitigates the risk of future recalls.
• Compound Profiling
Why you should attend this conference:
• Drug Discovery/Validation
• Future growth opportunities in the cell based assays market
• ow to reduce costs in the drug development process and produce more
H • Drug Delivery
accurate results earlier.
• Explore new techniques for lead discovery and target identification • Lead Generation
• iscover advances in core components required for the cell based assay
D
• In Vitro Sciences
platform
• ovel outputs using label-free detection methods that reduce interference
N • ADMET
in cellular signaling
• evelopments in software analysis for the outputs generated by different
D • Pre-clinical Development
cell based assays
• Medicinal Chemistry
• ell culture advances and methodology as the platform moves from 2D
C
to 3D
• Toxicology
• ell procurement using induced pluripotent stem cells to mimic human
C
disease pathology
• Stem Cell Technologies Platforms
• ecreating more accurate models of human disease and their response
R
to new drugs • Pharmacovigilance and Safety Testing
• Advances in process automation and management of data
• Chemistry and Bioapplications
I look forward to meeting you at the conference
Best regards • GPCR/Kinases/Molecular Pharmacology
• External/Contract Research
• Pharmacokinetics/Pharmacodynamics
Shahidul Islam
• Global Research and Development
Conference Producer
• Business Development
• Investment and Venture Capital
3. Day 1
Cell Based Assays Americas
Thursday July 19th, 2012
09:00 Registration and refreshments Gene-induction-assay: A useful approach for screening
14:00
existing drugs for new therapeutic indications in the
09:30 Opening address from the Chair areas of radioprotection anti-viral activity
Grace Wong • dentify AK-1 inducible genes involved in radioprotection and AK-2
I
CEO inducible genes involved in anti-viral activity
ActoKine Therapeutics
• alidate biological properties by gene silencing. Gene-induction-assay
V
approach will be used to screen existing drugs for properties that mimic
09:40 Session to be announced
the actions of AK-1 and AK-2 proteins.
Arijit Chakravarty
Senior Scientist • iscover new therapeutic indications for known drugs in the areas of
D
Millennium Pharmaceuticals radioprotection and prevention of infections by existing or emerging viruses
• xamine combined therapy of AK-1 or AK-2 with known drugs used in
E
10:20 High Content Screening Strategy for the rare
A the immunotherapy of cancer and viral diseases
Neurological disease Amyotrophic Lateral Sclerosis Grace Wong
• aboratory for Drug Discovery for Neurodegeneration (LDDN) is an
L CEO
academic drug discovery center that collaborates with the academic
ActoKine Therapeutics
community to accelerate the identification of novel therapeutics.
• myotrophic Lateral Sclerosis (ALS, Lou Gehrig’s disease) is a rare
A
neurodegenerative disease. There are at least six genes that can cause 14:40 Approaches to interpreting cell-based assay results
ALS. The genetic causes of ALS can provide a number of clues to the
mechanism of the disease as well as good potential therapeutic targets. in chemical biology
• e have done a high throughput high content screening assay to screen
W • nvestigation of new reporter enzymes to improve reporter-gene assay
I
our compound library for modulators of one of the genes targets that is a design and result interpretation
DNA/RNA binding protein, TDP-43 (TAR DNA-binding protein 43).
• se of focus libraries in the characterization of cell-based assays
U
• he stages to develop a high throughput high content assay will be
T
discussed along with the results from the screen. • igh-content approaches
H
Marcie Glicksman Douglas Auld
Director Lab for Drug Discovery Sr. Research Investigator I
Harvard NeuroDiscovery Center
Novartis
11:00 Morning refreshments
15:00 Afternoon Refreshments
11:20 High Content Imaging Assays that identify
Compounds which impair Mitochondrial and 15:20 Microfluidic system for on-chip high-throughput
Lysosomal function
whole-animal sorting and screening at sub-cellular
Sashi Nadanaciva
Principal Scientist resolution
Pfizer RD • creening whole organisms for HCA
S
• pplication to drug discovery and toxicity testing
A
12:00 Developing Reproducible and Scalable Methods to
Mehmet Fatih Yanik
Culture Stem Cells: From the Microwell Plate to the
Assoc. Professor
Bioreactor
MIT
• pproaches to finding the right culture conditions to meet your needs
A
• atrix, media and cell line considerations for optimal growth and
M
performance
16:00 Cellular systems that address the efficacy, selectivity,
• rivers for scale up, manufacturing concerns and potential bottlenecks
D
and mechanism of action of kinase inhibitors
• ags, bioreactors, micro-carriers, hollow fiber and fixed bed bioreactors
B
• Development and validation of a kinase cell-based assay platform
Jim Beltzer
Senior Cell Processing Specialist • tility for drug discovery (HTS, MOA determination, and lead optimization)
U
Terumo BCT
• Utility of the platform for selectivity analysis in cells
• Multiplex screening to improve efficiencies
12:40 Drug Discovery through 3D Engineered Tissue-Based
• Application to HTS for drug resistant mutant multiplexed analysis
Compound Analysis
• irst-in-class drug discovery through engineered tissue-based high
F Deborah Moshinsky
content analysis Founder and President
• ardiotoxicity assessments with human engineered heart tissues
C Cell Assay Innovations
• ulti-stage phenotypic screening for discovering a cardiac fibrosis
M
treatment
• ast Track drug discovery in a skeletal muscle disease treatment
F 16:40 Closing remarks from the Chair
Tetsuro Wakatsuki
Co-Founder Chief Scientific Officer
InvivoSciences 16:50 Networking Drinks
Take your discussions further and build new
13:00 Networking lunch relationships in a relaxed and informal setting
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2012
4. Day 2
Cell Based Assays Americas
Friday July 20th, 2012
09:00 Registration and refreshments 14:20 High-content screening in physiologically relevant
contexts
09:30 Opening address from the chair • o-cultures of stem cells can be screened by microscopy to study
C
Sashi Nadanaciva hematopoiesis and leukemia
Principal Scientist
• o-cultures of hepatocytes can be screened by microscopy to study liver
C
Pfizer RD
functions and hepatotoxicity
• . elegans can be screened by microscopy to study infection and
C
09:40 Development of phenotypic screening platforms for
metabolism in intact animals
the evaluation of putative autophagy enhancers
Regis Doyonnas Shantanu Singh
Senior Principle Scientist Research Fellow, Imaging Platform
Pfizer Broad Institute of Harvard and MIT
10:20 Novel Micropatterened Hepatocyte Co-culture
A
System for Drug Metabolism and Toxicity Studies 15:00 Afternoon refreshments
• eed for clinically-relevant and higher throughput liver models for drug
N
screening
• verview of a microscale hepatocyte co-culture system
O 15:20 Stem cell derived cardiomyocytes in cell based assays
• dvantages of the co-culture system: Relevant examples of how the
A mimicking in vivo tissue-like responses
microscale hepatocyte co-culture system could aid in toxicity prediction
and prediction of human in vivo metabolites • erivation and characteristics of cardiomyocytes from human pluripotent
D
stem cells
Okechukwu Ukairo
Sr. Principal Scientist • pportunities and limitation of current state-of-the-art stem cell derived
O
Hepregen Corporation cardiomyocytes in cell based assays
• ase studies of stem cell derived cardiomyocytes as alternatives to in vivo
C
11:00 Morning refreshments and ex vivo animal models
Peter Sartipy
11:20 novel, rapid and automated method for creating
A Senior Principal Scientist, Department Head
3D tissue models to study complex cell behaviour Cellectis Stem Cells
• What type of information can 3D tissue models provide?
• What is preventing widespread adoption of 3D tissue models?
• The route to scalable and tuneable 3D tissue models 16:00 Panel Discussion: Opportunities and challenges for
Grant Cameron human stem cells in drug screening
RAFT Development Director
TAP Biosystems • o models based on human dervied stem cells accurately reflect in-vivo
D
conditions?
12:00 Session to be announced • hat hurdles remain in the path to replacing animal testing with cellular
W
Robert Graves assays?
Senior Scientist
• thical dilemmas related to embryonic stem cells
E
GE Healthcare
Peter Sartipy, Senior Principal Scientist, Department Head
12:40 Networking lunch Cellectis Stem Cells
Marcie Glicksman, Director Lab for Drug Discovery
13:40 CNS based assays for automated drug discovery and Harvard NeuroDiscovery Center
profiling Thorsten Gorba, Director, CNS Assay Screening and Development,
• tem cell-based integrated platform for in vitro and in vivo screening and
S StemCells, Inc.
toxicity assays using the same human target cells of interest across the
entire continuum from discovery to preclinical testing Grace Wong, CEO, Actokine Therapeutics
• ultiplexed HCA and live cell assays to improve validation of leads
M
• ase studies of optimized protocols for automated human neural stem
C
cell production and of a proliferation screen 16:40 Chair’s closing remarks
Thorsten Gorba
Director, CNS Assay Screening and Development
StemCells, Inc. 16:50 End of Conference
Cell-Based Assays: World Market Prospects 2011-2026
RE
Are you looking for pharmaceutical RD market data - answers to save you time and effort, aiding decisions?
PO
Our new report shows you spending trends and revenue prospects for cell-based assays in pharma.
RT
We give market data for 2009 to 2026.
5. Partners
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
Silver Sponsor
InvivoSciences LLC is a frontier in developing next generation 3D cell culture and assay systems Sponsorship and
to provide unprecedented solutions in biomedical research, cosmetics, and toxicology screening. exhibition opportunities:
Current in vitro studies are confined largely to 2D cell culture models. However, most human cells
have 3D interactions. Application of our products, a high-throughput screening device (Palpator™) This event offers a unique opportunity to
and 3D cell culture systems, can narrow the gap between 2D cell culture studies and in vivo meet and do business with some of the
analysis. Effects of drug candidates, chemicals, and gene products on the physiological properties of key players in the pharmaceutical and
3D cell culture systems, forming reconstituted tissues, that mimic in vivo tissue/organ functions are quantified rapidly biotech industries. If you have a service
and cost-effectively. For further information please visit www.invivosciences.com or product to promote, you can do so at
this event by:
Exhibitors • Hosting a networking drinks
Matrical Bioscience is a leading supplier in the life-science research market through reception
matrical the development of innovative, quality products targeted for drug discovery and
bioscience
genomics applications. All products are cooperatively designed between our engineers • Taking an exhibition space at the
and biochemists/biologists to ensure a reliable cost-effective solution that meets or exceeds our customers’ conference
expectations. Matrical Bioscience is a worldwide supplier of automated storage platforms (MiniStore), automated • Advertising in the delegate
biobanking systems (NitroStore), automated assay platform (AutoMAP), automated cell culture systems documentation pack
(MACCS), high throughput sonication devices (SonicMan), universal microplate washer (SQUIRT), consumable
microwell plates in 96, 384, 1536 formats and tube technology for chemical and biological sample storage. • Providing branded bags, pens, gifts,
For further information please visit www.matrical.com etc.
If you would like more information on
TAP Biosystems provides advanced automation systems and services in 4 key the range of sponsorship or exhibition
application areas: cell-based testing, regenerative medicine, drug discovery and possibilities for visiongain's Cell Based
bioprocessing TAP will be exhibiting and presenting the new RAFT™ 3D cell Assays Americas Conference,
culture system. RAFT can be used as a platform technology to support assay development and secondary screening please contact us.
programs, as well as a broad range of cell biology research applications.
Damian Gorman,
SCIVAX Corporation is a Nano-technology company featuring Nano-imprinting. SCIVAX +44 (0)20 7549 9934
focus on commercialization of the Nano-imprinting application, and one of the products damian.gorman@
is our NanoCulture® Plate for biotechnology application. NanoCulture® Plate is a visiongainglobal.com
READY-TO-USE SBS format microplate, which can form 3D spheroids on the well bottom film with nano-
imprinted micro scaffold, without any matix and troublesome procedures. 3D spheroids can be cultured just
by adding standard cell culture medium to the well, and seeding. 3D spheroids of various cell types cultured
on our NanoCulture® Plate show in vivo like characters compared to monolayer cells, and is being used for About visiongain:
various application such as cancer drug screening, cell based assay, IPS/ES cell culture, etc. V
isiongain is a specialist business
For further information please visit www.scivax.com/usa/ information company focused on
providing cutting edge products and
Media Partners services across the Pharmaceutical/
PharmiWeb.com is the leading industry-sponsored portal for the pharmaceutical sector. Biotech, Telecommunications, Defence
Supported by most of the leading pharmaceutical corporations, PharmiWeb.com provides and Finance sectors, which include
dynamic real-time news, features, events listings and international jobs to industry professionals across Europe reports, conferences, online daily news
and the US. and offline news analysis and bespoke
For further information please email: corporate@pharmiweb.com consultancy. With a commitment to
innovation and excellence, visiongain
BIOTECHNOLOGY EUROPE is owned by BIOTECHNOLOGY WORLD. It is based and located offers flexible solutions to meet our
in Warsaw, Poland. Biotechnology World was founded in 2007 to provide the world’s clients’ business intelligence needs,
biotech and pharma information and market to make it universally accessible and useful for scientific and providing the right information
business processes. Its first step to fulfilling that mission was building the BIOTECHNOLOGY EUROPE at the right time to facilitate the
platform that will allow a quick spread of information in different channels. BIOTECHNOLOGY EUROPE offers commercial decision-making process.
companies completed internet public relations, publication and marketing solutions. One of the mains goals Our pharmaceutical products include
of BIOTECHNOLOGY EUROPE is to integrate the Biotech and Pharma Sector in Europe to global biotechnology, Pharma Business Daily, the leading
pharmaceutical and life science activities. daily email newsletter for the
For further information please visit www.biotechnology-europe.com pharmaceutical, biotech and healthcare
industries, and a range of independent,
InPharm is the online platform for exclusive pharmaceutical news, comment, contracts, high-quality, in-depth reports covering
services, jobs and events and is home to InPharmjobs.com, Pharmafile and Pharmafocus. focused and topical areas of concern.
For further information please visit: www.In-Pharm.com Our pharmaceutical conferences
address the hottest commercial,
Future Pharmaceuticals has forged powerful relationships with key industry leaders to
Driving the Industry Forward | www.futurepharmaus.com
regulatory and technical topics and
provide a platform for successful brand recognition, and for senior decision-makers to
provide an ideal forum for debate
have the means to procure and plan implementation strategies based on the topics covered. Positioned to
and networking for pharmaceutical
be an authoritative resource within top pharma companies as well as small, specialty, and biotech, Future
professionals from around the world.
Pharmaceuticals magazine is geared to create a deep penetration into a highly targeted and responsive
audience, bridging the gap between the industries’ top issues and the solutions top-tier vendors can provide. F
or further information, please
For further information please visit: www.futurepharmaus.com visit www.visiongain.com
6. Registration Form
Cell Based Assays Americas
July 19th - 20th, 2012, Boston, USA
For multiple bookings
Cell Based Assays
Photocopy this form Conf. code VG
Americas
Standard Prices July 19th – 20th, 2012
Location: The Seaport Hotel
Conference only Fee: £1299 (USD* 2006) Address:
One Seaport Lane
Boston
MA 02210
USA
*USD price is estimate only
Promotional Literature Distribution
Distribution of your company’s promotional literature to all conference attendees How to book
Fee: £999 VAT:
£199.80 Total:
£1198.80 Email: conferences@visiongainglobal.com
Web: http://www.visiongain.com/CellBasedAssaysUSA
Details UK Office:
Tel: +44 (0) 20 7336 6100
Fax: +44 (0) 20 7549 9932
Forename: Surname:
Visiongain Ltd
230 City Road
Job Title: Company: London
EC1V 2QY
UK
Main Switchboard Number:
General information
Address: Venue: The Seaport Hotel, One Seaport Lane, Boston, MA 02210, USA
Front Desk Phone: 001 617.385.4000 | Front Desk Fax: 001 617.385.4001
http://www.seaportboston.com/
Payment terms: Visiongain require the full amount to be paid before the conference. Visiongain
Ltd may refuse entry to delegates who have not paid their invoice in full. A credit card guarantee
Country: Postcode: may be requested if payment has not been received in full before the event. Visiongain Ltd reserves
the right to charge interest on unpaid invoices.
Substitutions/name changes or cancellations: There is a 50% liability on all bookings once
Phone: Fax: made, whether by post, fax, email or web. There is a no refund policy for cancellations received on or
after one month before the start of the event. Should you decide to cancel after this date, the full invoice
Email: must be paid. Conference notes will then be sent to you. Unfortunately, we are unable to transfer places
between conferences. However, if you cannot attend the conference, you may make a substitution/name
change at any time, as long as we are informed in writing by email, fax or post. Name changes and
Signature: substitutions must be from the same company or organisation and are not transferable between
countries. Please note that discounted delegates places at a visiongain event are non refundable.
I confirm that I have read and agree to the terms and conditions of booking Invoice alterations: There will be an administration charge of £50 for any changes to an invoice,
excluding substitutions/name changes, requested by the customer. This will be charged to the
customer by credit card prior to the changes being made.
Methods of payment Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executive
briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled
Payment must be made in sterling due to unforeseen events beyond the control of visiongain Ltd. If such a situation arises, we will try
to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or
By Mail: Complete and return your signed registration form together with your cheque expenses, which may be incurred by the customer as a consequence of the event being postponed or
payable to Visiongain Ltd and send to: visiongain Ltd, 230 City Road, London, EC1V 2QY, UK cancelled. We therefore strongly advise all our conference clients to take out insurance to cover the
cost of the registration, travel and expenses.
By Fax: Complete and fax your signed registration form with your credit card details Data Protection: Visiongain Ltd gathers and manages data in accordance with the Data
Protection Act 1988. Your personal information contained in this form may be used to update you on
to +44 (0) 20 7549 9932
visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We
may also share your data with external companies offering complementary products or services. If you
By Phone: Call us on +44 (0) 20 7336 6100 with your credit card details
wish for your details to be amended, suppressed or not passed on to any external third party, please
send your request to the Database Manager, visiongain Ltd, BSG House, 226-236 City Road, London,
Credit Card: Fill in your card details below and fax back to +44 (0) 20 7549 9932
By EC1V 2QY. Alternatively, you can visit our website at www.visiongain.com and amend your details.
Please allow approximately 30 days for your removal or update request to be applied to our database.
By Bank Transfer Following your removal or update request, you may receive additional pieces of communication from
visiongain Ltd during the transitional period, whilst the changes are coming into effect.
Please debit my credit card:
Fee: The conference fee includes lunch, refreshments and conference papers provided on the day.
Access MasterCard Visa American Express This fee does not include travel, hotel accommodation, transfers or insurance, (which we strongly
recommend you obtain).
Card number: VAT: VAT will be charged at the local rate on each conference. TaxPort USA Corp. specializes in
recovering cross-border VAT. Delegates may be able to recover VAT incurred by contacting TaxPort
Expiry Date: USA Corp.on: Tel: USA 802.860.0250 or +1.888.298.8296, Europe +41(0)21 310 01 50 or via
email on: vat@taxport-usa.com, vat@taxport-switzerland.com, vat@taxport-uk.com. For further
information please check Terms and Conditions on the visiongin.com web site
Security number (last 3 digits on back of credit card):
How we will contact you: Visiongain Ltd’s preferred method of communication is by email and
phone. Please ensure that you complete the registration form in full so that we can contact you.
Signature:
Unable to attend
Cardholder’s name: Obviously nothing compares to being there but you need not miss out. Simply tick the box and send
with your payment. You will receive speaker talks in PDFs two weeks after the event.
Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
News updates
Office use only
Please tick if you do not want to receive email news updates in the future
www.visiongain.com/CellBasedAssaysUSA